21,936 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Magnetar Financial LLC

Magnetar Financial LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 21,936 shares of the life sciences company's stock, valued at approximately $2,931,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WCM Investment Management LLC grew its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after purchasing an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after buying an additional 27,618 shares during the period. Geode Capital Management LLC grew its position in shares of Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock valued at $354,933,000 after buying an additional 48,018 shares during the last quarter. Primecap Management Co. CA increased its stake in shares of Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock valued at $328,158,000 after buying an additional 87,599 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after acquiring an additional 625,245 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Illumina Stock Down 0.6 %

NASDAQ ILMN traded down $0.49 during trading hours on Tuesday, hitting $87.53. The company's stock had a trading volume of 2,839,519 shares, compared to its average volume of 2,096,306. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company's 50-day simple moving average is $107.08 and its two-hundred day simple moving average is $127.97. The company has a market capitalization of $13.86 billion, a PE ratio of -11.40, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on ILMN. Canaccord Genuity Group reduced their target price on Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, March 11th. Robert W. Baird dropped their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Citigroup dropped their target price on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Royal Bank of Canada cut their price target on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.